Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation

The Lancet Oncology

Volumn 15, Issue 8, 2014, Pages

  Groll, Andreas H ^a   Castagnola, Elio ^b   Cesaro, Simone ^c   Dalle, Jean Hugues ^d   Engelhard, Dan ^e   Hope, William ^f   Roilides, Emmanuel ^g   Styczynski, Jan ^h   Warris, Adilia ⁱ   Lehrnbecher, Thomas ^j  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^h NICOLAUS COPERNICUS UNIVERSITY   (Poland)

ⁱ UNIVERSITY OF ABERDEEN   (United Kingdom)

^j GOETHE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BETA GLUCAN; CASPOFUNGIN; FLUCONAZOLE; FUNGUS ANTIGEN; GALACTOMANNAN; ITRACONAZOLE; MICAFUNGIN; NUCLEIC ACID; POSACONAZOLE; VORICONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ANTIGEN DETECTION; ASPERGILLOSIS; CANDIDEMIA; CANDIDIASIS; CHILD HEALTH CARE; CHILD SAFETY; CHILDHOOD CANCER; CLINICAL DECISION MAKING; CLINICAL FEATURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS DEVELOPMENT; CRYPTOCOCCOSIS; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEVER; GRANULOCYTOPENIA; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MUCORMYCOSIS; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYSTEMIC MYCOSIS;

ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LEUKEMIA; MYCOSES; OPPORTUNISTIC INFECTIONS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84903465253     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70017-8     Document Type: Review

References (82)

1. Dornbusch HJ, Manzoni P, Roilides E, Walsh TJ, Groll AH Invasive fungal infections in children. Pediatr Infect Dis J 2009, 28:734-737.
2. Groll AH, Tragiannidis A Update on antifungal agents for paediatric patients. Clin Microbiol Infect 2010, 16:1343-1353.
3. Sung L, Phillips R, Lehrnbecher T Time for paediatric febrile neutropenia guidelines-children are not little adults. Eur J Cancer 2011, 47:811-813.
4. Lestner JM, Smith PB, Cohen-Wolkowiez M, Benjamin DK, Hope WW Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. Br J Clin Pharmacol 2013, 75:1381-1395.
5. Herbrecht R, Flückiger U, Gachot B, Ribaud P, Tiebaut A, Cordonnier C Treatment of invasive candida and invasive aspergillus infections in adult haematological patients. Eur J Cancer 2007, 5(suppl 2):49-59.
6. Maertens J, Frere P, Lass-Flörl C, Heinz W, Cornely OA Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer 2007, 5(suppl 2):43-48.
7. Marchetti O, Cordonnier C, Calandra T Empirical antifungal therapy in neutropenic cancer patients with persistent fever. Eur J Cancer 2007, 5(suppl 2):32-42.
8. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011, 46:709-718. the Third European Conference on Infections in Leukemia.
9. Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2013, 98:492-504. the European Conference on Infections in Leukemia.
10. Cordonnier C, Calandra T The first European conference on infections in leukaemia: why and how?. Eur J Cancer 2007, 5(suppl 2):2-4.
11. Meunier F, Lukan C The first European conference on infections in leukaemia-ECIL1: a current perspective. Eur J Cancer 2008, 44:2112-2117.
12. Kish MA Guide to development of practice guidelines. Clin Infect Dis 2001, 32:851-854. the Infectious Diseases Society of America.
13. Hope WW, Castagnola E, Groll AH, et al. ESCMID* guideline for the diagnosis and management of candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012, 18(suppl 7):38-52. the ESCMID Fungal Infection Study Group.
14. ICH topic E 11 clinical investigation of medicinal products in the paediatric population. Note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99) European Medicines Agency, (accessed Aug 15, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002926.pdf.
15. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 20 December 2006 amending regulation 1901/2006 on medicinal products for paediatric use= European Community, (accessed Aug 15, 2013). http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1902/reg_2006_1902_en.pdf.
16. Dvorak CC, Fisher BT, Sung L, et al. Antifungal prophylaxis in pediatric hematology/oncology: new choices and new data. Pediatr Blood Cancer 2012, 59:21-26.
17. Tragiannidis A, Dokos C, Lehrnbecher T, Groll AH Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice. Drugs 2012, 72:685-704.
18. Tragiannidis A, Fegeler W, Rellensmann G, et al. Candidaemia in a European Paediatric University Hospital: a 10-year observational study. Clin Microbiol Infect 2012, 18:E27-E30.
19. Tragiannidis A, Roilides E, Walsh TJ, Groll AH Invasive aspergillosis in children with acquired immunodeficiencies. Clin Infect Dis 2012, 54:258-267.
20. Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008, 121:e1286-e1294.
21. Chiou CC, Walsh TJ, Groll AH Clinical pharmacology of antifungal agents in pediatric patients. Expert Opin Pharmacother 2007, 8:2465-2489.
22. Dornbusch HJ, Groll A, Walsh TJ Diagnosis of invasive fungal infections in immunocompromised children. Clin Microbiol Infect 2010, 16:1328-1334.
23. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821. the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Groupthe National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.
24. Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2012, 30:4427-4438. the International Pediatric Fever and Neutropenia Guideline Panel.
25. Rohrlich P, Sarfati J, Mariani P, et al. Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Pediatr Infect Dis J 1996, 15:232-237.
26. El-Mahallawy HA, Shaker HH, Ali Helmy H, Mostafa T, Razak Abo-Sedah A Evaluation of pan-fungal PCR assay and Aspergillus antigen detection in the diagnosis of invasive fungal infections in high risk paediatric cancer patients. Med Mycol 2006, 44:733-739.
27. Hovi L, Saxen H, Saarinen-Pihkala UM, Vettenranta K, Meri T, Richardson M Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr Blood Cancer 2007, 48:28-34.
28. Steinbach WJ, Addison RM, McLaughlin L, et al. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J 2007, 26:558-564.
29. Challier S, Boyer S, Abachin E, Berche P Development of a serum-based Taqman real-time PCR assay for diagnosis of invasive aspergillosis. J Clin Microbiol 2004, 42:844-846.
30. Maertens J, Maertens V, Theunissen K, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009, 49:1688-1693.
31. Desai R, Ross LA, Hoffman JA The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis. Pediatr Infect Dis J 2009, 28:283-286.
32. Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002, 40:1496-1499.
33. Roilides E, Pavlidou E, Papadopoulos F, et al. Cerebral aspergillosis in an infant with corticosteroid-resistant nephrotic syndrome. Pediatr Nephrol 2003, 18:450-453.
34. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME β-d-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011, 52:750-770.
35. Lamoth F, Cruciani M, Mengoli C, et al. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012, 54:633-643. the Third European Conference on Infections in Leukemia (ECIL-3).
36. Zhao L, Tang JY, Wang Y, et al. Value of plasma beta-Glucan in early diagnosis of invasive fungal infection in children. Zhongguo Dang Dai Er Ke Za Zhi 2009, 11:905-908. (in Chinese).
37. Mularoni A, Furfaro E, Faraci M, et al. High levels of beta-d-glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol 2010, 17:882-883.
38. Smith PB, Benjamin DK, Alexander BD, Johnson MD, Finkelman MA, Steinbach WJ Quantification of 1,3-beta-d-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol 2007, 14:924-925.
39. Loeffler J, Barnes R, Donnelly JP Standardization of Aspergillus PCR diagnosis. Bone Marrow Transplant 2012, 47:299-300. the European Aspergillus PCR Initiative.
40. Lass-Flörl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007, 45:e101-e104.
41. Rickerts V, Mousset S, Lambrecht E, et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007, 44:1078-1083.
42. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997, 15:139-147.
43. Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 1999, 17:796-805.
44. Taccone A, Occhi M, Garaventa A, Manfredini L, Viscoli C CT of invasive pulmonary aspergillosis in children with cancer. Pediatr Radiol 1993, 23:177-180.
45. Archibald S, Park J, Geyer JR, Hawkins DS Computed tomography in the evaluation of febrile neutropenic pediatric oncology patients. Pediatr Infect Dis J 2001, 20:5-10.
46. Marr KA, Laverdiere M, Gugel A, Leisenring W Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005, 40:1762-1769.
47. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004, 39:1407-1416. the National Institute of Allergy and Infectious Diseases Mycoses Study Group.
48. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010, 116:5111-5118. the Blood and Marrow Transplant Clinical Trials Network.
49. Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IG Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999, 42:591-600.
50. Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011, 155:318-327. the IMPROVIT Study Group.
51. Troke PF, Hockey HP, Hope WW Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011, 55:4782-4788.
52. Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012, 55:1080-1087.
53. Jang SH, Colangelo PM, Gobburu JV Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010, 88:115-119.
54. Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010, 95:1762-1768. the Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients with Allogeneic Stem Cell Transplants (VOSIFI) study group, the Infectious Diseases Working Partythe Infectious Diseases Working Party, European Group for Blood and Marrow TransplantationEuropean Group for Blood and Marrow Transplantation.
55. Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother 2008, 61:734-742.
56. Goldberg E, Gafter-Gvili A, Robenshtok E, Leibovici L, Paul M Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis. Eur J Cancer 2008, 44:2192-2203.
57. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997, 98:711-718.
58. Sandler ES, Mustafa MM, Tkaczewski I, et al. Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol 2000, 22:242-246.
59. Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010, 29:415-420. the Caspofungin Pediatric Study Group.
60. Caselli D, Cesaro S, Ziino O, et al. A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children. Br J Haematol 2012, 158:249-255.
61. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009, 48:1042-1051.
62. Girmenia C, Micozzi A, Gentile G, et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 2010, 28:667-674.
63. Tan BH, Low JG, Chlebicka NL, et al. Galactomannan-guided preemptive vs empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. Int J Infect Dis 2011, 15:e350-e356.
64. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52:427-431. the Infectious Diseases Society of America.
65. Marr KAS, Rottinghaus H, Jagannatha S, et al, and the Mycoses Study Group. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidalafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); London, UK; March 31-April 3, 2012. Abstract LB2812.
66. Caillot D, Thiébaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007, 110:2740-2746.
67. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797-802.
68. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006, 107:2888-2897. the Caspofungin Combination Therapy Study Group.
69. Cesaro S, Giacchino M, Locatelli F, et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis 2007, 7:28.
70. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44:2-12.
71. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36:1122-1131.
72. Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008, 52:1743-1750. the Global Scedosporium Study Group.
73. Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010, 54:4446-4450. the French Mycoses Study Group.
74. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006, 42:1398-1403.
75. Raad I, Chapman S, Bradsher R, Morrison V, Goldman M, Graybill J. Posaconazole salvage therapy for invasive fungal infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; Washington DC; Oct 30-Nov 2, 2004. Abstract M-669.
76. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008, 47:674-683.
77. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011, 14:164-176. the CLSI Subcommittee for Antifungal Testing.
78. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010, 48:1366-1377. the Global Antifungal Surveillance Group.
79. Zaoutis TE, Roilides E, Chiou CC, et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007, 26:723-727.
80. Dehority W, Willert J, Pong A Zygomycetes infections in pediatric hematology oncology patients: a case series and review of the literature. J Pediatr Hematol Oncol 2009, 31:911-919.
81. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:291-322.
82. Arendrup MC, Boekhout T, Akova M, et al. ESCMID/ECMM joint clinical guideline for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect 2013, the The ESCMID EFISG study group and ECMM, published online Sept 18. 10.1111/1469-0691.12360.